MEDICAL PHARMACY MANAGEMENT Utilization Management Programs Unique strategies are key components of a medical drug management program, and these programs are growing in popularity. In 2019, 59% of payers had dose optimization, 46% had vial rounding, and only 31% had weight-based dosing in place for oncology immunotherapies (see figures 37, 38, and 39). FIGURE 37: 2019 DOSE OPTIMIZATION PROGRAM Yes, it’s mandatory
Yes, it’s voluntary
FIGURE 38: 2019 VIAL ROUNDING
No
Yes, it’s mandatory
FIGURE 39: 2019 WEIGHT-BASED DOSING
Yes, it’s voluntary
No
Yes, it’s mandatory
Yes, it’s voluntary
No
11% 24%
28% Dose
(n=54)
20%
Weight-Based Dosing (n=54)
Rounding 54% Vial(n=54)
41% Optimization
22%
69%
31%
84%
53%
Immune Globulin (n=32)
Antihemophilic Factor (n=32)
Yes
No
47% BDAIDs (n=32)
Don’t know
Dose Optimization Savings (n=32)
72%
64%
Immune Globulin (n=25)
Yes
44% 3%
9%
Average Savings (n=14)†
†Savings self-reported.
23
MAGELLAN RX MEDICAL PHARMACY TREND REPORT / 2019
No
Oncology (n=25)
+/-5%
32%
+/-10%
Vial Rounding Savings (n=25)
52%
10%
82%
Average Savings (n=9)†
76%
Keytruda (n=17)
Don’t know
12%
Opdivo (n=17)
Yes
Vial Rounding Limits (n=25)
52% 53%
52%
BDAIDs (n=25)
No
Other (n=17)
Don’t know
Savings from Weight-Based Dosing (n=17)
16%
don’t know
29%
6%
48%
8%
Average Savings (n=2)†
65%